Cambridge Advisors Inc. held its stake in Merck & Company, Inc. (NYSE:MRK) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,182 shares of the company’s stock at the end of the third quarter. Cambridge Advisors Inc.’s holdings in Merck & Company were worth $1,197,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of the company. QCI Asset Management Inc. NY increased its stake in Merck & Company by 1.1% in the second quarter. QCI Asset Management Inc. NY now owns 2,382 shares of the company’s stock worth $137,000 after buying an additional 27 shares during the period. Bangor Savings Bank increased its stake in shares of Merck & Company by 0.4% in the third quarter. Bangor Savings Bank now owns 10,116 shares of the company’s stock valued at $632,000 after buying an additional 39 shares during the last quarter. Annex Advisory Services LLC increased its stake in shares of Merck & Company by 0.4% in the second quarter. Annex Advisory Services LLC now owns 12,081 shares of the company’s stock valued at $696,000 after buying an additional 43 shares during the last quarter. Landmark Financial Advisors LLC increased its stake in shares of Merck & Company by 0.7% in the second quarter. Landmark Financial Advisors LLC now owns 6,393 shares of the company’s stock valued at $368,000 after buying an additional 43 shares during the last quarter. Finally, Jackson Grant Investment Advisers Inc. increased its stake in shares of Merck & Company by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 5,234 shares of the company’s stock valued at $302,000 after buying an additional 44 shares during the last quarter. 72.43% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Merck & Company (NYSE:MRK)

Merck & Company, Inc. (NYSE:MRK) opened at 62.34 on Friday. The company has a market capitalization of $171.88 billion, a price-to-earnings ratio of 31.84 and a beta of 0.77. The company’s 50-day moving average is $60.78 and its 200-day moving average is $61.18. Merck & Company, Inc. has a 52-week low of $47.97 and a 52-week high of $65.46.

Merck & Company (NYSE:MRK) last announced its quarterly earnings results on Tuesday, October 25th. The company reported $1.07 EPS for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.08. The business earned $10.50 billion during the quarter, compared to analyst estimates of $10.17 billion. Merck & Company had a net margin of 13.76% and a return on equity of 24.25%. Merck & Company’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.96 EPS. On average, analysts expect that Merck & Company, Inc. will post $3.79 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Monday, January 9th. Stockholders of record on Thursday, December 15th were paid a $0.47 dividend. This is a positive change from Merck & Company’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend was Tuesday, December 13th. This represents a $1.88 annualized dividend and a dividend yield of 3.02%. Merck & Company’s dividend payout ratio is presently 95.92%.

ILLEGAL ACTIVITY NOTICE: “Cambridge Advisors Inc. Maintains Position in Merck & Company, Inc. (MRK)” was posted by Watch List News and is the propert of of Watch List News. If you are viewing this report on another publication, it was copied illegally and republished in violation of international copyright & trademark legislation. The legal version of this report can be read at http://www.watchlistnews.com/cambridge-advisors-inc-maintains-position-in-merck-company-inc-mrk/1061525.html.

MRK has been the subject of several recent analyst reports. Vetr raised shares of Merck & Company from a “strong sell” rating to a “sell” rating and set a $52.95 target price for the company in a research note on Monday, January 2nd. Bank of America Corporation raised shares of Merck & Company from a “neutral” rating to a “buy” rating and upped their target price for the company from $57.00 to $70.00 in a research note on Thursday, October 13th. Zacks Investment Research downgraded shares of Merck & Company from a “buy” rating to a “hold” rating in a research note on Thursday, November 10th. Jefferies Group downgraded shares of Merck & Company from a “hold” rating to an “underperform” rating and set a $48.00 target price for the company. in a research note on Monday, December 19th. Finally, Barclays PLC reaffirmed an “overweight” rating on shares of Merck & Company in a research note on Wednesday, October 12th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $66.34.

In other news, EVP Julie L. Gerberding sold 85,523 shares of the company’s stock in a transaction on Monday, November 7th. The shares were sold at an average price of $60.02, for a total value of $5,133,090.46. Following the completion of the sale, the executive vice president now owns 77,762 shares in the company, valued at approximately $4,667,275.24. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman Kenneth C. Frazier sold 140,000 shares of the company’s stock in a transaction on Thursday, November 10th. The stock was sold at an average price of $65.03, for a total transaction of $9,104,200.00. Following the completion of the sale, the chairman now owns 514,957 shares of the company’s stock, valued at approximately $33,487,653.71. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by insiders.

Merck & Company Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

5 Day Chart for NYSE:MRK

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.